Bladder Cancer Clinical Trial
— KEYNOTE-866Official title:
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866)
Verified date | October 2023 |
Source | Merck Sharp & Dohme LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.
Status | Active, not recruiting |
Enrollment | 907 |
Est. completion date | June 15, 2025 |
Est. primary completion date | June 15, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Have a histologically confirmed diagnosis of urothelial carcinoma (UC) / muscle invasive bladder cancer (MIBC) (T2-T4aN0M0 or T1-T4aN1M0) with predominant (=50%) urothelial histology. - Have clinically non-metastatic bladder cancer (N=1 M0) determined by imaging (computed tomography (CT) or magnetic resonance imaging (MRI)) of the chest/abdomen/pelvis. - Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND). - Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. - Have adequate organ function. - Male and female participants are eligible to participate if they agree to the contraception use as per study protocol. Exclusion Criteria: - Has a known additional malignancy that is progressing or has required active anti-cancer treatment =3 years of study randomization with certain exceptions. - Has received any prior systemic treatment for MIBC or non-invasive muscle bladder cancer (NMIBC - prior treatment for NMIBC with intravesical BCG/chemotherapy is permitted) or prior therapy with an anti- programmed cell death 1 (PD-1), anti-programmed cell death ligand 1/ ligand 2 (PD-L1/L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). - Has =N2 disease or metastatic disease (M1) as identified by imaging. - Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility criteria as per protocol. - Has received prior systemic anticancer therapy including investigational agents within 3 years of randomization or any radiotherapy to the bladder. - Has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC. - Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention. - Has a diagnosis of immunodeficiency or has a known history of human immunodeficiency virus (HIV) infection, Hepatitis B infection or known active Hepatitis C infection. - Has a known psychiatric or substance abuse disorder. - Has had an allogenic tissue/solid organ transplant. |
Country | Name | City | State |
---|---|---|---|
Australia | Eastern Health ( Site 1255) | Box Hill | Victoria |
Australia | Cairns Base Hospital ( Site 1257) | Cairns | Queensland |
Australia | Peninsula Health Frankston Hospital ( Site 1258) | Frankston | Victoria |
Australia | Mid North Coast Cancer Institute ( Site 1256) | Port Macquarie | New South Wales |
Australia | Southside Cancer Care Centre ( Site 1252) | Sydney | New South Wales |
Belgium | O.L.V. Ziekenhuis Aalst ( Site 0356) | Aalst | Oost-Vlaanderen |
Belgium | UZ Brussel ( Site 0358) | Brussels | Bruxelles-Capitale, Region De |
Belgium | AZ Maria Middelares Gent ( Site 0353) | Gent | Oost-Vlaanderen |
Belgium | Jessa Ziekenhuis ( Site 0360) | Hasselt | Limburg |
Belgium | CHU UCL Namur Site de Godinne ( Site 0354) | Yvoir | Namur |
Canada | Tom Baker Cancer Centre ( Site 0100) | Calgary | Alberta |
Canada | Nova Scotia Health Authority ( Site 0109) | Halifax | Nova Scotia |
Canada | Kingston Health Sciences Centre ( Site 0103) | Kingston | Ontario |
Canada | CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0105) | Montreal | Quebec |
Canada | Lakeridge Health ( Site 0104) | Oshawa | Ontario |
Canada | Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0 | Quebec City | Quebec |
Canada | Princess Margaret Cancer Centre ( Site 0107) | Toronto | Ontario |
Canada | Sunnybrook Research Institute ( Site 0110) | Toronto | Ontario |
Denmark | Herlev og Gentofte Hospital. ( Site 0402) | Herlev | Hovedstaden |
Denmark | Rigshospitalet University Hospital ( Site 0401) | Kobenhavn | Hovedstaden |
Denmark | Odense Universitetshospital ( Site 0403) | Odense | Syddanmark |
France | Institut de Cancerologie de l Ouest Site Paul Papin ( Site 0453) | Angers | Maine-et-Loire |
France | Institut Sainte Catherine ( Site 0454) | Avignon | Vaucluse |
France | CHU de Bordeaux- Hopital Saint Andre ( Site 0456) | Bordeaux | Aquitaine |
France | Centre Francois Baclesse ( Site 0459) | Caen | Calvados |
France | Centre Jean Perrin ( Site 0460) | Clermont-Ferrand | Puy-de-Dome |
France | Clinique Victor Hugo ( Site 0463) | Le Mans | Sarthe |
France | Centre Leon Berard ( Site 0465) | Lyon | Auvergne |
France | Hopital Robert Schuman ( Site 0452) | Metz | Moselle |
France | CHU de Montpellier - Hopital Saint-Eloi ( Site 0469) | Montpellier | Languedoc-Roussillon |
France | Centre Armoricain de Radiotherapie Imagerie medicale et Oncologie ( Site 0457) | Plerin | Cotes-d Armor |
France | CHU de Rouen ( Site 0493) | Rouen | Seine-Maritime |
France | Hopital Foch ( Site 0483) | Suresnes | Hauts-de-Seine |
Germany | Charite Universitaetsmedizin Berlin ( Site 0515) | Berlin | |
Germany | Vivantes Klinikum am Urban ( Site 0522) | Berlin | |
Germany | Universitaetsklinikum Carl Gustav Carus ( Site 0519) | Dresden | Sachsen |
Germany | Universitaetsklinikum Erlangen ( Site 0505) | Erlangen | Bayern |
Germany | Universitaetsklinikum Schleswig-Holstein-Campus Lubeck ( Site 0512) | Luebeck | Schleswig-Holstein |
Germany | Universitaetsklinikum Magdeburg A.o.R. ( Site 0516) | Magdeburg | Sachsen-Anhalt |
Germany | Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0502) | Tuebingen | Baden-Wurttemberg |
Hungary | Bajcsy Zsilinszki Korhaz es Rendelointezet ( Site 1001) | Budapest | |
Hungary | Debreceni Egyetem Klinikai Kozpont ( Site 1006) | Debrecen | |
Hungary | Petz Aladar Megyei Oktato Korhaz ( Site 1012) | Gyor | |
Hungary | Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1007) | Kaposvar | |
Hungary | Pecsi Tudomanyegyetem AOK ( Site 1009) | Pecs | Baranya |
Hungary | SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 1010) | Szeged | Csongrad |
Hungary | Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1002) | Szolnok | Jasz-Nagykun-Szolnok |
Ireland | Cork University Hospital ( Site 0722) | Cork | |
Ireland | Tallaght University Hospital ( Site 0710) | Dublin | |
Ireland | University Hospital Waterford ( Site 0723) | Waterford | |
Israel | Ha Emek Medical Center ( Site 0808) | Afula | |
Israel | Soroka Medical Center ( Site 0806) | Beer Sheva | |
Israel | Rambam Health Care Campus-Oncology Division ( Site 0802) | Haifa | |
Israel | Hadassah Ein Kerem Medical Center ( Site 0810) | Jerusalem | |
Israel | Shaare Zedek Medical Center ( Site 0809) | Jerusalem | |
Israel | Meir Medical Center ( Site 0803) | Kfar Saba | |
Israel | Rabin Medical Center ( Site 0804) | Petach Tikva | |
Israel | Sheba Medical Center ( Site 0801) | Ramat Gan | |
Israel | Sourasky Medical Center ( Site 0807) | Tel Aviv | |
Israel | Yitzhak Shamir Medical Center ( Site 0805) | Zerifin | |
Italy | A.O.U. Policlinico Vittorio Emanuele - Presidio Gaspare Rodolico ( Site 0559) | Catania | |
Italy | Istituto Nazionale Studio e Cura dei Tumori ( Site 0551) | Milano | |
Italy | Policlinico di Modena ( Site 0553) | Modena | Emilia-Romagna |
Italy | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori ( Site 0552) | Napoli | |
Italy | Fondazione Salvatore Maugeri IRCCS. ( Site 0554) | Pavia | |
Italy | Azienda Ospedaliera San Camillo Forlanini ( Site 0560) | Roma | |
Italy | Policlinico Gemelli di Roma ( Site 0558) | Roma | Abruzzo |
Italy | Azienda Ospedaliera Santa Maria Terni ( Site 0557) | Terni | |
Japan | Chiba Cancer Center ( Site 1506) | Chiba | |
Japan | Harasanshin Hospital ( Site 1515) | Fukuoka | |
Japan | Saitama Medical University International Medical Center ( Site 1505) | Hidaka | Saitama |
Japan | Hirosaki University Hospital ( Site 1502) | Hirosaki | Aomori |
Japan | Hiroshima City Hiroshima Citizens Hospital ( Site 1513) | Hiroshima | |
Japan | Nara Medical University Hospital ( Site 1510) | Kashihara | Nara |
Japan | National Cancer Center Hospital East ( Site 1504) | Kashiwa | Chiba |
Japan | Nagano Municipal Hospital ( Site 1516) | Nagano | |
Japan | Osaka Metropolitan University Hospital ( Site 1512) | Osaka | |
Japan | Sapporo Medical University Hospital ( Site 1501) | Sapporo | Hokkaido |
Japan | Tokushima University Hospital ( Site 1514) | Tokushima | |
Japan | Tokyo Medical and Dental University Hospital ( Site 1517) | Tokyo | |
Japan | Ehime University Hospital ( Site 1508) | Toon | Ehime |
Japan | University of Tsukuba Hospital ( Site 1503) | Tsukuba | Ibaraki |
Japan | Yokosuka Kyosai Hospital ( Site 1509) | Yokosuka | Kanagawa |
Korea, Republic of | National Cancer Center ( Site 1354) | Goyang-si | Kyonggi-do |
Korea, Republic of | Seoul National University Bundang Hospital ( Site 1356) | Seongnam-si | Kyonggi-do |
Korea, Republic of | Asan Medical Center ( Site 1355) | Seoul | |
Korea, Republic of | Korea University Anam Hospital ( Site 1351) | Seoul | |
Korea, Republic of | Samsung Medical Center ( Site 1353) | Seoul | |
Korea, Republic of | Seoul National University Hospital ( Site 1352) | Seoul | |
Mexico | Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. ( Site 0300) | Aguascalientes | |
Mexico | Centro Estatal de Cancerologia de Chihuahua ( Site 0253) | Chihuahua | |
Mexico | Centro de Urologia Avanzada del Noreste S.A. de C.V. ( Site 0254) | Monterrey | Nuevo Leon |
Mexico | Instituto Nacional de Cancerologia ( Site 0256) | Tlalpan | |
Poland | Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1060) | Bielsko-Biala | Slaskie |
Poland | Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 1068) | Bydgoszcz | Kujawsko-pomorskie |
Poland | Europejskie Centrum Zdrowia Otwock ( Site 1057) | Otwock | Mazowieckie |
Poland | Luxmed Onkologia sp. z o. o. ( Site 1051) | Warszawa | Mazowieckie |
Poland | Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1062) | Wroclaw | Dolnoslaskie |
Russian Federation | Ivanovo Regional Oncology Dispensary ( Site 0852) | Ivanovo | Ivanovskaya Oblast |
Russian Federation | Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0861) | Krasnoyarsk | Krasnoyarskiy Kray |
Russian Federation | Kursk Regional Clinical Oncology Dispensary ( Site 0854) | Kursk | Kurskaya Oblast |
Russian Federation | Central Clinical Hospital with outpatient Clinic ( Site 0856) | Moscow | Moskva |
Russian Federation | FSBI ""United Hospital with Polyclinic"" of the Administrative Department of the President of the Ru | Moscow | Moskva |
Russian Federation | Bayandin Murmansk Regional Clinical Hospital ( Site 0859) | Murmansk | Murmanskaya Oblast |
Russian Federation | Volga District Medical Center Federal Medical and Biological Agency ( Site 0857) | Nizhny Novgorod | Nizhegorodskaya Oblast |
Russian Federation | Omsk Clinical Oncology Dispensary ( Site 0865) | Omsk | Omskaya Oblast |
Russian Federation | Leningrad Regional Oncology Center ( Site 0868) | Saint Petersburg | Sankt-Peterburg |
Russian Federation | Saratov State Medical University n.a. V.I.Razumovskiy ( Site 0866) | Saratov | Saratovskaya Oblast |
Russian Federation | Clinical Hospital Saint Luka ( Site 0867) | St. Petersburg | Sankt-Peterburg |
Russian Federation | Clinic of Bashkortostan State Medical University ( Site 0869) | Ufa | Baskortostan, Respublika |
Spain | Hospital del Mar ( Site 0653) | Barcelona | |
Spain | Hospital San Pedro de Alcantara ( Site 0654) | Caceres | Extremadura |
Spain | H. de Gerona Dr. Josep Trueta ( Site 0651) | Girona | Gerona |
Spain | Hospital Universitario La Paz ( Site 0661) | Madrid | |
Spain | Hospital Universitario Ramon y Cajal ( Site 0660) | Madrid | Madrid, Comunidad De |
Spain | Hospital Universitario San Carlos ( Site 0663) | Madrid | |
Spain | Hospital Universitario Quiron Madrid ( Site 0657) | Pozuelo de Alarcon | Madrid, Comunidad De |
Spain | Hospital Nuestra Sra. de Valme ( Site 0658) | Sevilla | |
Spain | Instituto Valenciano de Oncologia - IVO ( Site 0662) | Valencia | Valenciana, Comunitat |
Sweden | Laenssjukhuset Ryhov ( Site 1205) | Jonkoping | Jonkopings Lan |
Sweden | Cancercentrum ( Site 1204) | Umea | Vasterbottens Lan |
Sweden | Akademiska Sjukhuset ( Site 1201) | Uppsala | Uppsala Lan |
Thailand | Faculty of Medicine Siriraj Hospital ( Site 1452) | Bangkok | Krung Thep Maha Nakhon |
Thailand | Ramathibodi Hospital. ( Site 1451) | Bangkok | Krung Thep Maha Nakhon |
Thailand | Maharaj Nakorn Chiangmai Hospital ( Site 1453) | Chiang Mai | |
Thailand | Srinagarind Hospital ( Site 1454) | Khon Kaen | |
Turkey | Hacettepe Universitesi Tip Fakultesi ( Site 0911) | Ankara | |
Turkey | Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0910) | Istanbul | |
Turkey | TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 0906) | Istanbul | |
Turkey | Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 0901) | Istanbul | |
Turkey | Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0909) | Konya | |
Turkey | Sakarya Universitesi Tip Fakultesi ( Site 0913) | Sakarya | |
Turkey | Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi ( Site 0904) | Trabzon | |
Ukraine | Cherkasy Regional Oncology Dispensary ( Site 0959) | Cherkasy | Cherkaska Oblast |
Ukraine | Dnipropetrovsk City Multidiscipline Clinical Hosp. 4 of DRC ( Site 0951) | Dnipro | Dnipropetrovska Oblast |
Ukraine | Regional Oncological Hospital ( Site 0956) | Dnipro | Dnipropetrovska Oblast |
Ukraine | MI Dnipr Regional Clinical Hospital named after I.I. Mechnikov ( Site 0963) | Dnipropetrovsk | Dnipropetrovska Oblast |
Ukraine | CNPE "Regional Center of Oncology" ( Site 0958) | Kharkiv | Kharkivska Oblast |
Ukraine | Reg. Clinical Center of Urology and Nephrology n.a. V. I. Shapoval ( Site 0969) | Kharkiv | Kharkivska Oblast |
Ukraine | Kyiv City Clinical Oncology Center ( Site 0960) | Kyiv | |
Ukraine | National Cancer Institute of the MoH of Ukraine ( Site 0962) | Kyiv | Kyivska Oblast |
Ukraine | Lviv Regional Clinical Hospital ( Site 0955) | Lviv | Lvivska Oblast |
Ukraine | Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 0967) | Lviv | Lvivska Oblast |
United Kingdom | Aberdeen Royal Infirmary ( Site 0708) | Aberdeen | Aberdeen City |
United Kingdom | Kent and Canterbury Hospital ( Site 0709) | Canterbury | England |
United Kingdom | Imperial College Healthcare NHS Trust ( Site 0721) | London | London, City Of |
United Kingdom | The Royal Marsden Foundation Trust ( Site 0702) | London | London, City Of |
United Kingdom | Norfolk & Norwich University Hospital NHS Foundation Trust ( Site 0725) | Norwich | Norfolk |
United Kingdom | Lister Hospital ( Site 0715) | Stevenage | Hertfordshire |
United Kingdom | Torbay Hospital ( Site 0704) | Torquay | Devon |
United Kingdom | Royal Cornwall Hospital ( Site 0703) | Truro | |
United States | UNM Comprehensive Cancer Center-Clinical Research Office ( Site 0045) | Albuquerque | New Mexico |
United States | Charleston Area Medical Center ( Site 0023) | Charles Town | West Virginia |
United States | University Hospitals Cleveland Medical Center ( Site 0038) | Cleveland | Ohio |
United States | Henry Ford Hospital ( Site 0039) | Detroit | Michigan |
United States | Inova Schar Cancer Institute ( Site 0007) | Fairfax | Virginia |
United States | Parkview Cancer Institute ( Site 0077) | Fort Wayne | Indiana |
United States | MD Anderson Cancer Center ( Site 0063) | Houston | Texas |
United States | Indiana University Melvin and Bren Simon Cancer Center ( Site 0004) | Indianapolis | Indiana |
United States | Scripps MD Anderson ( Site 0010) | La Jolla | California |
United States | Morristown Medical Center ( Site 0015) | Morristown | New Jersey |
United States | Ochsner Medical Center ( Site 0049) | New Orleans | Louisiana |
United States | New York University Perlmutter Cancer Center ( Site 0008) | New York | New York |
United States | AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0005) | Orlando | Florida |
United States | Allegheny General Hospital ( Site 0048) | Pittsburgh | Pennsylvania |
United States | Portland VA Medical Center ( Site 0084) | Portland | Oregon |
United States | Northwest Medical Specialties, PLLC ( Site 0061) | Puyallup | Washington |
United States | Mercy Hospital Saint Louis ( Site 0064) | Saint Louis | Missouri |
United States | Providence Saint John's Health Center ( Site 0075) | Santa Monica | California |
United States | New England Cancer Specialists ( Site 0070) | Scarborough | Maine |
United States | Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0033) | Seattle | Washington |
United States | Central Texas Veterans Healthcare System ( Site 0057) | Temple | Texas |
United States | Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021) | Tulsa | Oklahoma |
United States | Georgetown University Medical Center ( Site 0022) | Washington | District of Columbia |
United States | UMass Memorial Medical Center ( Site 0051) | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Merck Sharp & Dohme LLC |
United States, Australia, Belgium, Canada, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Sweden, Thailand, Turkey, Ukraine, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Event-Free Survival (EFS) | EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery; failure to undergo RC surgery in participants with residual disease and any radiographical disease present; gross residual disease left behind at the time of surgery; local or distant recurrence based on investigator assessments and/or biopsy, or death due to any cause. | Up to approximately 60 months | |
Secondary | Pathologic Complete Response (pCR) Rate | pCR rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as assessed by blinded independent central review (BICR). | Up to approximately 72 months | |
Secondary | Overall Survival (OS) | Overall survival is defined as the time from randomization to death due to any cause. | Up to approximately 72 months | |
Secondary | Disease-Free Survival (DFS) | DFS is defined as the time from post-surgery baseline scan until the first occurrence of either local or distant recurrence as assessed by investigator by CT or MRI and/or computerized tomography (CT) or magnetic resonance imaging (MRI) and or biopsy or death from any cause. | From approximately 20 weeks up to approximately 72 months | |
Secondary | Pathologic Downstaging (pDS) Rate | pDS rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of Up to approximately 72 months |
| |
Secondary | Number of Participants Who Experienced an Adverse Event (AE) | An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. | Up to approximately 72 months | |
Secondary | Number of Participants Who Discontinued Study Treatment Due to an AE | An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. | Up to approximately 12 months | |
Secondary | Number of Participants Who Experienced Perioperative Complications | An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. | Up to approximately 12 months | |
Secondary | Change in Patient-Reported Outcomes from Baseline in Total Score of Functional Assessment of Cancer Therapy - General (FACT-G) | The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score can range from 0 to 108. | Baseline, Up to approximately 72 months | |
Secondary | Change in Patient-Reported Outcomes from Baseline in Total Score of FACT-Bladder- (FACT-BI-Cys) | Total Score of FACT BI-Cys is the sum of FACT-G total score and FACT-Bl-Cys score. FACT-Bl-Cys contains 17 items on the bowel, bladder, and sexual symptoms following cystectomy. The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score of FACT-Bl-Cys can range from 0 to 168. | Baseline, Up to approximately 72 months | |
Secondary | Change in Patient-Reported Outcomes from Baseline in FACT-BI-Cys-Trial Outcome Index (TOI) | FACT-Bl-Cys Trial Outcome Index (TOI) is the sum of FACT-G PWB score, FWB score, and FACT-Bl-Cys score. FACT-Bl-Cys contains 17 items on the bowel, bladder, and sexual symptoms following cystectomy. The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score of FACT-Bl-Cys TOI can range from 0 to 116. | Baseline, Up to approximately 72 months | |
Secondary | Change in Patient-Reported Outcomes from Baseline in EuroQol Five-Dimensional Questionnaire (EQ-5D-5L) Visual Analog Score (VAS) | The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. In the EQ-5D-5L VAS, the participant rates his or her general state of health at the time of the assessment on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. | Baseline, Up to approximately 72 months | |
Secondary | Time to Deterioration (TTD) in the Total Score of FACT-G | The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0-4, with higher scores indicating higher HRQoL. TTD is defined as the time from baseline to the first onset of patient-reported outcomes (PRO) deterioration. For the FACT-G questionnaire, deteriorations are defined as a decrease of 7 points or more (out of 108) from baseline in total score. | Up to approximately 72 months | |
Secondary | TTD in EQ-5D-5L VAS | The EQ-5D-5L is a standardized instrument for use as a measure of health outcome and includes 5 health state dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In the EQ-5D-5L VAS, the participant rates his or her general state of health at the time of the assessment on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. TTD is defined as the time from baseline to the first onset of PRO deterioration. For the EQ 5D-5L, deterioration is defined as a decrease of 7 points or more from baseline in the VAS. | Up to approximately 72 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |